CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.51 USD | -3.46% |
|
-2.33% | -40.38% |
| 06:28pm | CureVac Begins Early Stage Portion of Investigational Vaccine Trial | MT |
| 04:47pm | CureVac Hires New Chief Business Officer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Calendar
2024-04-23
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.43
EUR
Average target price
11.42
EUR
Spread / Average Target
+370.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.38% | 582M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2CoV 'Highly Comparable' With Pfizer's mRNA Vaccine
